Skip to content

Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults

Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05933642
Enrollment
132
Registered
2023-07-06
Start date
2023-07-02
Completion date
2023-12-31
Last updated
2023-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Aminophylline, Furosemide, Critically ill, Adults, Intensive Care Unit (ICU)

Brief summary

The goal of this RCT is to compare the effectiveness of aminophylline and furosemide combination vs furosemide alone in producing effective diuresis in critically ill adults in ICU. ICU patients with the need of improved diuresis will be recruited and given either infusion of aminophylline and furosemide combination or furosemide alone, and their hourly urine output will be monitored to compare their effectiveness.

Interventions

DRUGAminophylline

aminophylline 150mg

frusemide 120mg

Sponsors

University of Malaya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Recruited patient randomised into intervention vs control group by non clinical personnel, trial drugs dilution by research assistant, drug administered to patient by staff nurses, data collection by independent group

Intervention model description

double blind, randomised, controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years old and above who are admitted to the ICU of UMMC during the study period * Oliguric patients, with the need for improved diuresis at clinician discretion - defined as urine output \<0.5ml/kg/hour

Exclusion criteria

* Patient refusal for participation of study * Patients with known hypersensitivity reaction to aminophylline or furosemide * Patients with history of tachyarrhythmias, seizures, aspartate aminotransferase or alanine aminotransferase \> 3 times normal, or hypothyroidism. Patient with existing peptic ulcer disease or coagulopathy with INR \> 1.5

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with effective diuresis at 6 hours post intervention6 hours post interventionwhether effective diuresis is achieved at 6 hours post intervention. Effective diuresis is defined as urine output \>0.5ml/kg/hour based on patient's actual body weight

Secondary

MeasureTime frameDescription
Mean duration of infusion to achieve effective diuresis post interventionUp to 6 hours post interventionsTime in hours taken for infusion to achieve effective diuresis post intervention. Effective diuresis is defined as urine output \>0.5ml/kg/hour based on patient's actual body weight
Changes in urine output at 6 hours post intervention6 hours post interventionsDifference of hourly urine output (ml/hour) measured immediately before starting intervention and 6 hours post intervention
Percentage of patients with effective diuresis at 2 hours post intervention2 hours post interventionwhether effective diuresis is achieved at 2 hours post intervention. Effective diuresis is defined as urine output \>0.5ml/kg/hour based on patient's actual body weight
Changes in serum eGFR at 1 day post intervention1 day post interventionDifference of serum eGFR in mL/min/1.73m2 on the day of intervention and one day after intervention
Percentage of patients requiring Renal Replacement Therapy (RRT)throughout ICU stay, an average of 1 monthPercentage of patients undergoing RRT during ICU stay
Changes in serum creatinine at 1 day post intervention1 day post interventionDifference of serum creatinine in mmol/l on the day of intervention and one day after intervention

Countries

Malaysia

Contacts

Primary ContactHaw Shyan Ng
plue_chris@yahoo.co.uk+6 016 483 7722

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026